Western Media Focusses On Big Pharma’s Search for a Coronavirus Vaccine While Suppressing Coverage of High Dose Intravenus Vitamin C to Save Lives in China

Not a day passes without some hyped up media story of how big-pharma is racing to the rescue of humanity with its search for a coronavirus vaccine. There are over 40 companies now searching for a vaccine. Collectively they are spending huge sums of money supported by lavish amounts of tax payer cash. Estimates of how soon a vaccine can be produced vary wildly but most estimates agree that it is unlikely to happen this year. It goes without saying that the first to market with a usable vaccine stands to make billions of dollars.

The mainstream media, scientific and political establishments are completely under the spell of big pharma. Governments reassure the public that they’re doing everything in their power to protect them with a variety of measures. These range from mass lock downs and trillion dollar bailouts for big business to limited amounts of helicopter money for the citizens of wealthier countries.

Regardless of where you live if you have to go to hospital with symptoms of the coronavirus the key question facing you is: will you be able to leave walking out front door or will you end up being wheeled out the basement back door?

The mainstream media in cahoots with governments and the medical establishment are suppressing any news regarding the use of a cheap, safe and easy to produce treatment for coronavirus patients. Maybe its because this treatment is being used in Chinese hospitals to save lives. Let’s face it there has been no let up in Cold War 2.0 during the current pandemic.

Dr. Andrew W. Saul, Editor in chief of the Orthomolecular Medicine News Service, sums up the Western big pharma approach nicely when he says:

“Medical orthodoxy obsessively focuses on searching for a vaccine and/or drug for coronavirus COVID-19). While they are looking for what would be fabulously profitable approaches, we have with vitamin C an existing, plausible, clinically demonstrated method to treat what coronavirus patients die from: severe acute respiratory syndrome, or pneumonia.’’

On 17 March a group of Chinese physicians held a video conference to discuss the use of high dose intravenous vitamin C for patients with moderate to severe cases of corona virus. The keynote speaker at this meeting was Dr. Enqian Mao, chief of the emergency medicine Department of Ruiijin hospital in Shanghai.

Dr Mao is also a senior member of the expert team at the Shanghai Public health Centre, where all coronavirus patients have been treated from the Shanghai area. Dr Mao was also a co-author of the medical protocol for the treatment of coronavirus that has been adopted by the Shanghai Medical Association and the government of Shanghai. This medical protocol also advocates the use of high-dose intravenous vitamin C for the treatment of mild, moderate and severe cases of the coronavirus.

Over the last decade Dr Mao has been using high-dose intravenous vitamin C (IVC) to treat patients with a variety of acute medical conditions ranging from pancreatitis and sepsis to surgical wound healing. When the coronavirus epidemic first broke out he and several other colleagues thought that high-dose intravenous C could be a potential treatment for patients presenting with the coronavirus. Their recommendation for the use of high-dose intravenous vitamin C as a treatment was adopted by the Shanghai expert team.

Dr. Richard Cheng, an American-Chinese doctor currently based in Shanghai has given a report of this meeting. He notes that:

“Dr. Mao stated that his group treated ~50 cases of moderate to severe cases of Covid-19 infection with high dose IVC. The IVC dosing was in the range of 10,000 mg – 20,000 mg a day for 7-10 days, with 10,000 mg for moderate cases and 20,000 for more severe cases, determined by pulmonary status (mostly the oxygenation index) and coagulation status. All patients who received IVC improved and there was no mortality. Compared to the average of a 30-day hospital stay for all Covid-19 patients, those patients who received high dose IVC had a hospital stay about 3-5 days shorter than the overall patients. Dr. Mao discussed one severe case in particular who was deteriorating rapidly. He gave a bolus of 50,000 mg IVC over a period of 4 hours. The patient’s pulmonary (oxygenation index) status stabilized and improved as the critical care team watched in real time. There were no side effects reported from any of the cases treated with high dose IVC. ‘’

Dr Cheng also reported that he had a separate meeting with Dr. Sheng Wang, Professor of critical medicine of Shanghai’s 10th Hospital, Tongji University College of medicine. At this meeting Professor Weng said that there were several important lessons to be learned from Shanghai’s experience treating patients with the coronavirus. The most important lesson was:

Early and high-dose IVC is quite helpful in helping Covid-19 patients. The data is still being finalized and the formal papers will be submitted for publication as soon as they are complete.’’

Professor Wang also stated that coronavirus patients displayed a high rate of hyper-coagulability, i.e. an abnormally increased tendency toward blood clotting, which is best treated with heparin.

He also stated that it was vitally important for front line medical professionals to, ‘wear protective clothing at the earliest opportunity for intubation and other emergency rescue measures.’ The American health authorities shouldtake notice of this considering that pictures of nurses in New York wearing black plastic refuse sacks have been appearing on social media.

Richard Chang has also noted that Professors Mao and Weng have stated that high-dose intravenous vitamin C is being used as a treatment for coronavirus patients in other hospitals around China.

Not surprisingly, reports of this cheap, safe treatment, that has been pioneered in China, have been being completely ignored by Western governments and the medical establishments that are beholden to the big pharmaapproach to the current pandemic.

Thankfully, there are doctors in the West who are not blinded by the close minded approach pursued by their governments and so called medical experts. Apparently, doctors at several hospitals in New York, which is the epicentre of the coronavirus epidemic in America, have started to use the pioneering treatments coming out of China.

Dr. Andrew G. Weber, a pulmonologist and critical-care specialist affiliated with two Northwell Health facilities on Long Island, has said that coronavirus patients admitted to intensive care immediately receive 1,500 mg of intravenous vitamin C. This dosage is then repeated 3-4 times a day.

According to Dr. Weber this treatment regime is based upon the experimental use of high-dose vitamin C in Shanghai’s hospitals. He told the New York Post:

“The patients who received vitamin C did significantly better than those who did not get vitamin C. It helps a tremendous amount, but it is not highlighted because it’s not a sexy drug.”

Apparently, high-dose intravenous vitamin C is been used in hospitals across New York. Sadly, its use appears to be patchy and is dependent upon the whims of individual doctors rather than being part of any systematic medical protocol.

As the global death toll soars higher we can only hope that more and more doctors will follow in the footsteps of their Chinese colleagues and have the courage to use a safe and cheap treatment that is totally at odds with the big pharma approach currently followed by the World Health Organisation and most governments. The current approach used by many Western Governments has been slow, clumsy and ill informed putting the interests of big business above saving the lives of ordinary people.

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.


Comment on Global Research Articles on our Facebook page

Become a Member of Global Research


Articles by: Dr. Leon Tressell

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]